05.31.18
Cambrex Corp., a manufacturer of small molecule innovator and generic APIs, began a $5 million expansion of its lab facilities in Karlskoga, Sweden, to augment capability and capacity for process development and scale up, handling of potent substances, crystallization studies and solid phase characterization. Construction on the 600 m2 building is expected to be complete in 2Q19.
The expansion will create space for a new technical lab with walk-in hoods for large scale lab syntheses up to 10 liters, where engineers and chemists will undertake tech transfer studies. The new investment will also enable handling of potent substances at a large lab scale, high pressure reactions and parallel synthesis for API route scouting and development.
In addition to the technical lab, the expansion will feature two analytical development and quality control labs and additional office space for 12 additional scientists and chemists, bringing the total headcount to 60.
“We have a rich history in chemistry at our Karlskoga site, dating back 120 years to Alfred Nobel himself in 1896,” said Bjarne Sandberg, managing director, Cambrex Karlskoga. “The new laboratory expansion will enhance our ability to provide global customers with scientific and chemical excellence.”
In 2017 Cambrex upgraded its continuous flow capabilities in Karlskoga with a dedicated commercial-scale unit, capable of producing multiple metric tons of high purity API intermediates per year. The company also completed the installation of multiple continuous flow reactor platforms at its process development facility in High Point, NC. This investment is focused on development of processes to supply clinical as well as commercial demand for chemical syntheses.
The expansion will create space for a new technical lab with walk-in hoods for large scale lab syntheses up to 10 liters, where engineers and chemists will undertake tech transfer studies. The new investment will also enable handling of potent substances at a large lab scale, high pressure reactions and parallel synthesis for API route scouting and development.
In addition to the technical lab, the expansion will feature two analytical development and quality control labs and additional office space for 12 additional scientists and chemists, bringing the total headcount to 60.
“We have a rich history in chemistry at our Karlskoga site, dating back 120 years to Alfred Nobel himself in 1896,” said Bjarne Sandberg, managing director, Cambrex Karlskoga. “The new laboratory expansion will enhance our ability to provide global customers with scientific and chemical excellence.”
In 2017 Cambrex upgraded its continuous flow capabilities in Karlskoga with a dedicated commercial-scale unit, capable of producing multiple metric tons of high purity API intermediates per year. The company also completed the installation of multiple continuous flow reactor platforms at its process development facility in High Point, NC. This investment is focused on development of processes to supply clinical as well as commercial demand for chemical syntheses.